Median Technologies SA represents values of innovation, collaboration, and integrity. With a strong corporate philosophy focused on transforming the world of imaging and data analysis in the healthcare industry, Median Technologies SA aims to improve patient outcomes by providing cutting-edge solutions. The company's commitment to innovation is reflected in its advanced technologies and expertise in medical imaging, while its collaborative approach encourages partnerships with leading institutions and industry players. With a foundation of integrity, Median Technologies SA strives to build trust and deliver high-quality results to its clients, making it a reliable and respected name in the field.

Median Technologies SA is primarily present in multiple countries and regions. With a global presence, the company operates in key markets such as the United States, Europe, and Asia. It has established a strong foothold in countries like France, where its headquarters are located, as well as the United States, China, Japan, and South Korea. With its innovative solutions and services in medical imaging and artificial intelligence, Median Technologies SA has expanded its reach worldwide, collaborating with leading healthcare institutions and pharmaceutical companies.

Median Technologies SA has achieved significant milestones throughout its history in the stock market. The company has successfully established itself as a leader in the field of imaging solutions and services for medical diagnostic and drug development. It has notably developed innovative imaging technologies that enable better management of cancer patients, aiding in the early detection, characterization, and monitoring of diseases. Furthermore, Median Technologies SA has also formed strong partnerships with renowned research centers and pharmaceutical companies to collaborate on cutting-edge projects. Through its dedication to advancing medical imaging, the company has consistently demonstrated its commitment to improving patient outcomes and shaping the future of precision medicine.

Median Technologies SA is a leading medical imaging software solutions provider. Founded in France in 2002, the company develops innovative technologies to improve the diagnosis and treatment of various diseases, with a particular focus on oncology. With a proven track record of collaborations with global pharmaceutical and biotech companies, Median Technologies has established itself as a trusted partner in clinical research and drug development. The company's advanced imaging biomarkers and software platforms play a vital role in improving efficiency and precision in medical imaging analysis. Through its continued dedication to innovation, Median Technologies continues to make significant contributions to the field of medical imaging.

The main competitors of Median Technologies SA in the market include companies such as PerkinElmer, Inc., GE Healthcare, and Siemens Healthineers.

Median Technologies SA is primarily active in the healthcare and life sciences industries.

The business model of Median Technologies SA revolves around providing innovative imaging solutions and services to the healthcare industry. The company specializes in developing and commercializing advanced technologies for medical imaging and analysis. With a focus on precision medicine, Median Technologies SA offers software solutions and expertise in imaging biomarkers, radiomics, and theranostics. By leveraging its proprietary technology, Median Technologies SA enables healthcare providers and pharmaceutical companies to enhance patient diagnosis, treatment, and drug development processes. The company's strong commitment to research and development, along with its partnerships with leading institutions and organizations, positions it as a trusted global leader in medical imaging solutions.

KGV-d ei saa praegu Median Technologies jaoks arvutada.

KUV-d ei ole võimalik hetkel Median Technologies jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Median Technologies on 8/10.

oodatud Median Technologies käive on 28,48 mln. EUR.

oodatud Median Technologies kasum on −19,08 mln. EUR.

The company Median Technologies SA is a leading company in the field of medical image processing, specializing in the development of software solutions for the biopharmaceutical industry. The business model of Median Technologies is based on three main business areas: iBiopsy, Imaging, and iCRO. iBiopsy is a cloud-based platform developed by Median Technologies to analyze and interpret medical images of patients. The platform uses machine learning to create predictive models that can help doctors make more precise diagnoses and better treatment decisions. The iBiopsy platform builds on the work of radiologists, pathologists, bioinformaticians, and engineers to perform comprehensive analysis of medical images. The Imaging business of Median Technologies includes a wide range of solutions to support clinical studies, from protocol development to data analysis. Median's Imaging solutions help companies understand the effectiveness of drugs, ensure patient safety, and accelerate the market launch of new drugs. iCRO, the abbreviation for "Imaging Clinical Research Organization," is an important part of Median Technologies' business. iCRO provides services in image analysis and data collection to help companies conduct clinical studies. iCRO services include planning and conducting clinical studies, data analysis and interpretation, and support in image interpretation. Median Technologies specializes in developing software solutions tailored to the needs of biopharmaceutical companies. Median Technologies' solutions help companies improve clinical studies, accelerate product development, and improve outcomes for patients. The products and services of Median Technologies are widely used in the biopharmaceutical industry. Median serves over 70 clients, including major pharmaceutical companies, small and medium-sized biotech companies, as well as leading universities and research institutions worldwide. To market the products and services of Median Technologies, the company works closely with customers, partners, and distribution channels that expand the company's reach worldwide. Median Technologies has also established strategic partnerships and alliances with other companies in the biopharmaceutical industry to further strengthen its ability to develop innovative solutions. In summary, the business model of Median Technologies SA is focused on the development of software solutions to improve medical image analysis and interpretation. The company offers a wide range of products and services that are used throughout the biopharmaceutical industry. Through close collaboration with customers, partners, and distribution channels, and strategic alliances, the company strengthens its position in the market and its ability to innovate.

Median Technologies maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Median Technologies jaoks arvutada või ettevõte ei maksa dividende välja.

Median Technologies ISIN on FR0011049824.

Median Technologies WKN on A1JCLB.

Median Technologies tähis on ALMDT.PA.

Viimase 12 kuu jooksul maksis Median Technologies dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Median Technologies tõenäoliselt dividendi summas 0 EUR.

Median Technologies praegune dividenditootlus on .

Median Technologies maksab kvartaalset dividendi. See makstakse välja kuudel .

Median Technologies maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Median Technologies on liigitatud sektorisse 'Tervis'.

Viimase Median Technologies dividendide saamiseks 7.7.2025 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 7.7.2025.

Viimane dividendimakse toimus 7.7.2025.

Aastal 2024 maksis Median Technologies 0 EUR dividende.

Median Technologies dividendid makstakse välja EUR.